Mali interdisciplinary hospital is integrating conventional, regenerative and precision medicine. It divides into 11 departments, there are 35 beds in total, including 12 intensive care beds, 23 general beds, 2 emergency and operating rooms, 1 plastic surgical room, 1 Gastro-colonoscopic room. Focus on round-trip treatment with modern medical technology to reduce the cost of hospitalization and the healing time. It also integrating regenerative medicine to repair the body and precision medicine for preventing and treating chronic non-communicable diseases (NCDs) with better results, we provide these services in a greenery atmosphere. Allowing clients to receive the following benefits.

1. Far away from NCDs & It’s complication

2. Good quality of life

3. Youthful lively life

4. Longevity

Dr. Thanaphat Pomyukon is a general surgeon (ศัลยแพทย์ทั่วไป). Thai medical license no. ว.50550. He earned his M.D. from the Faculty of Medicine, Chulalongkorn University. He also holds the Thai Board Diploma in General Surgery from Roi Et Hospital, Ministry of Public Health.

His clinical focus includes hernias and hemorrhoids. He also treats breast lumps and gallstones. He manages digestive system diseases. He performs gastrointestinal endoscopy, including gastroscopy and colonoscopy.

Languages: Thai (primary) and English (professional clinical level).

外科治療：泌尿器科におけるすべての手術。

医療サービスの一般管理。患者のポリクリニック受診。評議会への参加。難しいケースにおける「セカンドオピニオン」、臨床状況の専門評価。マスタークラス、ワークショップ、ウェブセミナーの組織と開催。

医師が持つ技術：

前立腺のTUIPおよび膀胱形成のTOIP。

前立腺のレーザー摘除、膀胱腫瘍のレーザー切解。

前立腺腺のレーザー蒸発。

尿道狭窄のレーザー切開

接触レーザー尿管-、腎盂-および膀胱結石破砕

経皮（ミニ）腎結石破砕術

腎内逆行性および前進手術（RIRSおよびAIRS）ボアリ手術。

損傷または狭窄の場合の尿道形成術

膀胱経由の前立腺切除術

膀胱造瘻術 - 開放型およびトロカー

腎瘻

根治的腎摘出術（腹腔鏡を含む）

腎破裂の縫合

腎盂切石術

尿管切石術

骨盤尿管形成術（腹腔鏡）

腎嚢胞の除去（嚢胞切除術）（腹腔鏡）

尿管膀胱吻合術

尿管皮膚瘻造設術

膀胱の腹腔内および後腹膜破裂に対する手術

去勢術

副睾丸切除術

ベルクマンおよびウィンケルマン手術

外傷および炎症性疾患によるポルチコ器官の修正

静脈瘤、割礼、経皮腎瘻、腎結石破砕のためのイバニセビッチおよびマルマール手術

腎嚢胞の穿刺

Areas of Interests

• Breast cancer
• Lung cancer
• Colorectal cancers
• Gynecological and urogenital cancers
• Molecular Oncology

Education:

• Kızıltepe Anatolian High School 2001
• Dicle University Faculty of Medicine 2007
• Istanbul Medeniyet University Göztepe Training and Research Hospital 2014
• Kartal City Hospital 2021
• Associate Professor of Medical Oncology 2023

Experience:

• Liv Hospital Ulus
• Adıyaman University Training and Research Hospital
• Istanbul Umraniye Training and Research Hospital
• Istanbul Umraniye Training and Research Hospital

Research:

• Phase II, Randomized, Open-Label, Multicenter Study to Comparatively Evaluate the Efficacy and Safety of GDC-9545 and Physician-Preferred Endocrine Monotherapy in Previously Treated, Estrogen Receptor Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer Patients, Other ( International), Dr. Murat Ayhan
• Phase III, Randomized, Evaluating the Efficacy and Safety of Palbociclib and Fulvestrant with Gdc-0077 Compared with Placebo in Patients with Pik3ca-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer. Double Blind, Placebo Controlled Study, Other (International), Dr. Murat Ayhan
• Randomized, Multicenter, Phase Ib/III Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Atezolizumab Compared to Intravenous Atezolizumab in Patients with Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer, Other (International) Dr. Murat Ayhan
• Randomized, Controlled, Multicenter, Open-Label Study Including Observation Follow-Up for PSMA-PET-Negative Patients, Investigating the Efficacy and Safety of Addition of Apalutamide to Radiotherapy and LHRH Agonist in PSMA-PET-Positive High-Risk Hormone-Sensitive Prostate Cancer Patients, Other (International) Dr. Murat Ayhan
• Biomarker Study to Identify Patients with Advanced Stage Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations-42756493BLC0002, Other (International), Dr. Murat Ayhan
• Publications:
• Ayhan M, Turan N, Köstek O, et all. Does the efficacy of regorafenib differ in chemotherapy refractory metastatic colorectal cancer patients who had mucinous pathology compared to those who had non-mucinous pathology? Curr Probl Cancer. 2021 Jun;45(3):100670. doi: 10.1016/j.currproblcancer.2020.100670.
• Ayhan M, Odabas H, Turan N, et all. Factors affecting the mortality rate of patients with cancer hospitalized with COVID-19: a single center's experience. J Chemother. 2021 Nov;33(7):499-508. doi: 10.1080/1120009X.2021.1923153.
• Ayhan M, Laçin Ş, Özyükseler DT, et all. Does systemic anti-tumor therapy increase COVID-19 risk in patients with cancer? J Oncol Pharm Pract. 2021 Sep;27(6):1461-1467. doi: 10.1177/10781552211015762.
• Ayhan M, Abamor E, Coban Kokten S, et al. Value of FDG PET/CT in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. EJMI 2022;6(2):165–175.
• Ayhan M, Terzioglu K. Experience With Rapid Drug Desensitization With Chemotherapeutics; A SingleCentre Retrospective Study. EJMI 2021;5(3):380–387.
• Doğan A, AYHAN M. Survival analysis of patients with triple-negative breast cancer: a single-center experience. Journal of Oncological Sciences, 8(2), 94-99., Doi: 10.37047/jos.2022-89749
• Terzioğlu K, Ayhan M. Comparative Assessment of Platinum Salts and Taxane Group Hypersensitivity Reactions, The Role of Skin Tests in Diagnosis? J Oncol Pharm Pract. 2021 Nov 30:10781552211050084. doi: 10.1177/10781552211050084.
• Tacar SY, Selcukbiricik F, Yilmaz M, Erturk K, Murat Sarici A, Gulturk I, Ayhan M, Tural D. Nivolumab for metastatic uveal melanoma: a multicenter, retrospective study. Melanoma Res. 2021 Oct 1;31(5):449-455. doi: 10.1097/CMR.0000000000000744.
• Özyurt E, Özçelik S, Sürmeli H, Çelik M, Ayhan M, Özçelik M. Side effects of immune-checkpoint inhibitors: Can multiple side effects be seen in a patient? J Oncol Pharm Pract. 2022 Mar;28(2):462-465. doi: 10.1177/10781552211038136.
• Dülgar Ö, Öven BB, Atcı MM, Arıkan R, Ay S, Ayhan M, Selvi O, Ozyukseler DT, Bayram E, Özcan E, Yasin Aİ, Gümüş M. Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy? Expert Rev Anticancer Ther. 2022 Jul;22(7):773-780. doi: 10.1080/14737140.2022.2076670.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study. J Cancer Res Clin Oncol. 2022 Jun;148(6):1501-1508. doi: 10.1007/s00432-021-03748-7.
• Volume I, Kucukarda A, Atcı MM, Ayhan M, et all. Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study. Tumori. 2022 Feb;108(1):19-25. doi: 10.1177/03008916211037739.
• Dogan I, Ayhan M, Gurbuz M, et all. The frequency and prognostic significance of ABO/Rh blood groups in male breast cancer patients: A multicenter study. Medicine (Baltimore). 2022 Sep 2;101(35):e30147. doi: 10.1097/MD.0000000000030147.
• Ozcelik M, Oyman A, Cil I, Duzgun O, Ozkan OF, Ayhan M. Cytoreductive Surgery versus Systemic Chemotherapy alone in Isolated Peritoneal Carcinomatosis of Colorectal Origin. J Coll Physicians Surg Pak. 2021 Nov;31(11):1308-1313. doi: 10.29271/jcpsp.2021.11.1308.
• Başoğlu T, Sakin A, Erol C, Ayhan M, et all. Real life experienceof patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study. J Chemother. 2022 May 17:1-8. doi: 10.1080/1120009X.2022.2073159.
• Özdemir Ö, Zengel B, Yildiz Y, Ayhan M, et all. The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study. Anticancer Drugs. 2022 Aug 1;33(7):663-670. doi: 10.1097/CAD.0000000000001310.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study). J Cancer Res Clin Oncol. 2022 Sep 1. doi: 10.1007/s00432-022-04252-2.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study. Future Oncol. 2022 Jul;18(23):2573-2582. doi: 10.2217/fon-2022-0083.
• Topcu A, Atci MM, Secmeler S, Besiroglu M, Ayhan M, Ozkan M, Bozkurt O, Urakci Z, Ay S, Geredeli C, Yasin AI, Turk HM. Efficacy of trastuzumab and potential risk factors on survival in patients with HER2-positive metastatic gastric cancer. Future Oncol. 2021 Nov;17(31):4157-4169. doi: 10.2217/fon-2021-0398.
• Bilgin B, Sendur MAN, Yucel S, Ayhan M, et all. Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study. J Cancer Res Clin Oncol. 2021 Jul;147(7):2145-2152. doi: 10.1007/s00432-020-03501-6.
• Atci MM, Akagunduz B, Demir M, Arikan R, Ay S, Ozer M, Ayhan M, Cil I, Demir N, Ozyurt N, Karakaya G, Cevik GT, Onder AH, Selvi O, Sakin A. The impact of adjuvant oxaliplatin and tumor sidedness on the overall survival of stage IIB colon cancer patients: a multicentre study. J Chemother. 2023 Feb;35(1):19-28. doi: 10.1080/1120009X.2022.2040770.
• Tataroglu Ozyukseler D, Ay S, Turan M, Alkan G, Ayhan M, Surmeli H, et al. The Systemic Inflammation Response Index as a Prognostic Marker in Advanced Pancreatic Cancer. EJMI 2022;6(3):367–373.
• Yıldız F, Ayhan M, Demir H, et all. Comparing the efficacy of cabazitaxel in secondline and third-Line treatment of metastatic castration-resistant prostate cancer: a multi-center experience from Turkey. International Journal of Contemporary Medical Research, 7(9), 112-116.,Doi: 10.21276/ijcmr.2020.7.9.30
• Terzioğlu K, Ayhan M. Distribution of allergens detected on patch tests of patients with allergic contact dermatitis and investigation of their atopic background. Annals of Medical Research, 29(5), 422-426., doi: 10.5455/annalsmedres.2021.07.490
• Arikan R, Atci MM, Ay S, Ayhan M, et all Prognostic significance of mucinous histology in left sided metastatic colorectal cancers with wild type RAS and evaluation of backbone chemotherapy regimens. Oncol Lett. 2023 Apr 5;25(5):208. doi: 10.3892/ol.2023.13795.
• Almuradova E, Yalcin S, Arıkan R, Ayhan M, Demir H, Cevik GT, Karaca M, Petekkaya I, Karabulut B. Survival of Patients With Metastatic Rectum Cancer Who Underwent Metastasectomy Following Conversion Chemotherapy Sans Pelvic Radiotherapy: A Turkish Oncology Group Study. Cureus 2023 May 17;15(5):e39119. doi: 10.7759/cureus.39119.
• Topcu A, Besiroglu M, Atci MM, Ayhan M, et all. Second-line Therapy after Trastuzumab Failure in HER2-Positive Metastatic Gastric Cancer: A Real-life Data. EJMI 2023;7(2):153–161. DOI: 10.14744/ejmi.2023.22720
• Book Writing:
• Drug interactions and side effects of targeted agents, Section name: (Small molecule tyrosine kinase inhibitors; ROS-1 targeted therapies (Crizotinib, Seritinib)) (2021)., AYHAN MURAT, Turkish Clinics Journal of Medical Sciences, Editor: Mehmet Aliustaoglu, Publishing number:1, Number of Pages 92, ISBN:978-625-401- 466-6, Turkish
• Approach to gastrointestinal stromal tumors and neuroendocrine tumors, Department name: (Medical approach in primary non-gastrointestinal neuroendocrine tumors) (2020)., AYHAN MURAT, Akademisyen Yayınevi, Editor: Anılır Ender, Number of editions: 1, Number of Pages 382, ISBN: 9786052585719, Turkish
• Internal medicine emergencies, Department name: (Oncological emergencies) (2022)., YILDIRIM SEDAT, AYHAN MURAT, Efe Academic Publishing, Editor: Serdar Olt, Number of editions: 1, Number of Pages 232, ISBN: 978-625-8324-66- 2, Turkish
• Physicians' chemotherapy cancer drug manual 2020, Section name: (Common chemotherapy regimens in clinical practice) (2022)., SÜMBÜL AHMET TANER, ALKAN ALI, AKSOY ASUDE, AYHAN MURAT, et all, Türkiye Klinikleri Journal of Medical Sciences, Editor: EDWAR CHU, VINCENT T. DEVITA, SAADDETIN KILIÇKAP, CEMIL BILIR, SELÇUK SEBER, Number of editions: 1, Number of pages 772, ISBN: 978-625-401-290- 7, Turkish (Book Translation)

Member of SICOB - Italian Society of Obesity Surgery and ACOI - Association of Italian Hospital Surgeons                                               

Dr Braun is a board-certified general surgeon with over 25 years of experience specializing in gastrointestinal surgery, particularly in the treatment of gastroesophageal reflux disease (GERD) through Fundoplication surgery. He has performed over 500 successful Nissen and Toupet Fundoplication procedures, with a focus on minimally invasive laparoscopic techniques. His expertise extends to diagnosing complex cases of GERD and offering comprehensive treatment plans to improve patient outcomes.

He has carried out his main training experiences in various international institutions and specialization courses in general and digestive system surgery, including a two-year training internship at Johns Hopkins University, Division of Hepatobiliary Pancreatic Surgery and numerous courses in Madrid, with Prof. E. Moreno Gonzales (Curso Internacional de Actualizaciòn en chirurgia General y del Aparato Digestivo) or in New Orleans (Medical Education at the 90th Annual Clinical Congress of the American College of Surgeons).

Dr. Braun has extensive expertise in the field of digestive surgery. He has focused on implementing advanced protocols and optimizing surgical techniques, while maintaining high standards of safety and patient care. He has collaborated with a multidisciplinary team to provide an integrated and personalized approach in the management of obese or digestive disorder patients, improving quality of life and reducing post-operative complications.

Education

• Faculty of Medicine: Trakya University, 1982-1988
• Radiation Oncology Residency: Şişli Etfal Training and Research Hospital, 1994-1998
• Radiation Oncology Residency: Princess Margaret Hospital Toronto, 1996
• Phytotherapy Master's Degree: Istanbul University Faculty of Pharmacy, 2017-2018

Experience

• Professor, Head of Department: Health Sciences University Bursa Faculty of Medicine, Department of Radiation Oncology, 2021-2024
• Professor, Head of Department: Health Sciences University Izmir Faculty of Medicine, Department of Radiation Oncology, 2021-2024
• Professor: Department of Radiation Oncology, Health Sciences University Istanbul Hamidiye Faculty of Medicine, 2021-2024
• Lecturer Gelisim University SMYO, 2013-2020

Medical Interests

• Breast Cancer / Intraoperative Radiotherapy
• Gynaecological Cancers / Brachytherapy Applications
• Gastrointestinal System Tumours
• Prostate Cancer / Hydrogel Space Oar Certificate and Application
• Lung Cancers
• Brain Tumours
• Head and Neck Cancers

助手教授. メルテム・トパルゴクチェリ・セラム M.D. - 医療腫瘍学

医学分野の興味と活動

• 胃腸系がん
• 卵巣がん

職務経験と教育

• 医療腫瘍学部門, ライブ病院, ウルス
• 腫瘍学部門, 保健省オクメイダニトレーニング＆リサーチホスピタル
• 医療腫瘍学部門, 腫瘍研究所, イスタンブール大学医学部
• 内科部門, 保健省オクメイダニトレーニング＆リサーチホスピタル
• イスタンブール大学医学部
• ユスキュダルアメリカンアカデミー フォー ガールズ

所属

• トルコ医療腫瘍学会
• イスタンブール乳がん研究グループ
• ユスキュダルアメリカンアカデミー卒業生協会

研究と出版

国際: 3

国内: 9

国内学会で発表及び出版された報告: 7

手作業翻訳: 1

この医師は2004年にアンカラ大学医学部を卒業し、2011年までにアクデニズ大学で産科と婦人科の専門医資格を取得しました。婦人科腫瘍学の専門性をさらに磨くため、2014年にEtlik Zübeyde Hanım Hospitalでサブスペシャリゼーションを完了し、2018年にはMemorial Sloan Kettering Cancer Centerでロボット手術を観察しました。臨床の焦点は婦人科がんにおけるピンホール手術、前がん性子宮頸部病変、卵巣がん手術を含みます。Liv Hospital UlusとEtlik Zübeyde Hanım Hospitalでの豊富な経験を持ち、ESGOおよびENYGOのメンバーでもあります。

メルダン・ファイダ博士はトルコのリヴ病院の放射線腫瘍学者です。博士は4D放射線療法とIMRT、腫瘍の高精度照射を行っています。教授は放射線腫瘍学で19年の経験を持っています。

職歴

1993 - 2004年 - ファイダ博士はイスタンブール大学の医学部で学びました。彼はノースカロライナ大学（米国）で放射線外科を学びました。

2012年以降、教授はイスタンブールの癌研究所で実践を続けています。現在、ファイダ教授はトルコで最大の医療ネットワークであるリヴ病院で働いています。

医師予約

医師は放射線診断を行います：MRI、CT（コンピュータ断層撮影）、PET-CT（陽電子放出断層撮影）。

Bookimedでファイダ博士の相談をリクエストしてください。Bookimedの医師が診断詳細を明らかにするためにご連絡いたします。

科学活動

メルダン・ファイダ博士は16の国際会議に参加しました。教授はトルコ版で11の科学論文、国際出版で25の論文を執筆しています。

組織メンバーシップ

• トルコ放射線腫瘍学会（TROD）；
• アメリカ放射線腫瘍学会；
• ヨーロッパ治療放射線学および腫瘍学会（ESTRO）。

研究と出版 

• • 国際記事：25 
• • 国内記事：11 
• • 国際ジャーナルの査読者：2 
• • 国際会議発表：16

Dr Erdem Gelegen is an ophthalmologist with over 20 years of experience in cataract, refractive, retinal, glaucoma, and corneal/anterior segment care. He performs phacoemulsification with premium intraocular lenses. He provides laser vision correction for myopia, hyperopia, and astigmatism. He treats diabetic retinopathy, age-related macular degeneration, retinal detachment, keratoconus, and anterior segment disorders, including corneal transplants.

He graduated from Istanbul University Cerrahpaşa Faculty of Medicine in 1999. He completed his ophthalmology residency at Okmeydanı Training and Research Hospital in 2004. He is known for precise microsurgery and the use of advanced ophthalmic technologies.

この医師は、Fortis Multidisciplinary Hospitalの腫瘍外科のディレクターであり、悪性腫瘍、乳がん、肺がん、消化器がんの四肢温存手術を専門としています。

著名な経歴を持ち、この医師はRajiv Gandhi Cancer Instituteでロボット手術部門を設立しました。この医師は、Oswal Cancer Hospital、Tata Memorial Hospital、BLK Medical Complexなどのいくつかの著名な機関でコンサルタントを務めました。さらに、Jaramshila Narayana Hospital、Batra Hospital、Rajiv Gandhi Cancer Instituteで上級コンサルタントの役割を果たしました。

この医師は、インドのGovernment Medical College Amritsarで訓練を受けました。

Dr. Cevat Azeroglu is a radiologist. He graduated from the Tabriz University Faculty of Medicine in 1987. He completed his radiology specialization at Ondokuz Mayıs University in 2011. Born in 1959, he provides advanced imaging to support accurate, timely decisions for many specialties.

His expertise includes conventional radiology with X-rays for musculoskeletal and chest disease. He performs ultrasound of the abdomen, thyroid, vessels, and soft tissues. He interprets CT and MRI for neurological, cardiovascular, and oncologic conditions. He practices interventional radiology with image-guided, minimally invasive procedures. He also focuses on oncologic imaging for staging and follow-up. He is known for diagnostic precision, use of modern imaging tools, and strong teamwork.

Dr. Ozlem Yogurtcu is a general surgeon with extensive experience. She graduated from Dokuz Eylul University Faculty of Medicine. She completed her general surgery residency at Haseki Training and Research Hospital, 1st Surgical Clinic. She is fluent in English.

Her practice includes gastrointestinal surgery (gallbladder disease, hernias, appendicitis, other gastrointestinal conditions). It also includes endocrine surgery (thyroid, parathyroid, adrenal) and breast surgery (benign and malignant conditions). She treats emergency and trauma cases. She performs minimally invasive laparoscopic procedures.

She is known for precise surgery and a patient-centered approach.

Head of the Onco-Gynecology Department

Academic Education:

• Bachelor of Medicine and Surgery. University of Barcelona.
• Doctor in medicine. University of Barcelona. Extraordinary prize for doctoral thesis.
• Training in translational research thanks to a post-doctoral stay at Memorial Sloan-Kettering Cancer Center (New York, USA).

Professional Experience:

• Medical Oncologist specialized in urological cancer. Her areas of expertise are prostate cancer, kidney, bladder and urinary tract cancer, and testicular cancer.
• She currently works as a Senior Consultant in the Medical Oncology Service of the Hospital Clínic de Barcelona, ​​where she is responsible for urological cancer. 
• At HM Delfos, from Medical Oncology, she is responsible for the care of patients with urological cancer, from a multidisciplinary approach in coordination with the different specialists (urology, radiotherapy, pathology) through joint work and the Tumor Committee. She is also responsible for the introduction of new therapies and the development of clinical trial projects in this area.

Scientific and Teaching Activity:

• Associate Professor of the Faculty of Medicine of the Clinical Hospital. University of Barcelona. 
• Teaching in the subject of Medical Oncology, of the 5th year of the Degree in Medicine and Surgery at the University of Barcelona. She has been the director of several Final Degree projects for medical students in ​​urological cancer.
• Teacher and Director of the subject "Prostate Cancer" of the Master of Biomedicine. University of Barcelona.
• Teacher and Director of the subject "Comprehensive management of the uro-oncological patient", of the Master of Uro-Oncology of Advanced Medical Competences. University of Barcelona. 
• Direction of several doctoral theses on prostate cancer.
• Extensive experience in the training of Residents in Medical Oncology at the Clinical Hospital de Barcelona.
• Extensive teaching experience in scientific courses and symposiums.
• Internship tutor for students of the Master in Art Therapy at Escuela Metáfora. Art therapy in cancer patients at Hospital Clinic.
• Coordinator of Mindfulness training workshops in Oncology.
• Clinical research:   Extensive experience as principal investigator of multiple clinical trials, phase I, II and III, of new therapies in urological cancer.
• Translational research: Researcher at the August Pi i Sunyer Biomedical Research Institute (IDIBAPS). Leader of the Prostate Cancer working group, within the Translational Genomics Laboratory and Targeted Therapy in Solid Tumors. Her fundamental line of research is based on the investigation of resistance mechanisms to prostate cancer treatments and the study of biomarkers that allow progress towards personalized medicine in this disease.
• She has published more than 140 scientific articles in international journals.

Areas of Professional Interest:

• Her interest as a professional is to provide the best care for patients with urological cancer from all areas: the best care on an individual basis and offer them the best available treatment or the possibility of having access to new treatments within clinical trials. 
• In addition, she has a great interest in promoting comprehensive care for patients and their families.

Pediatric Oncologist

この医師は9年以上の経験を持つ腫瘍内科医であり、乳がん、大腸がん、肺がん、前立腺がんの管理を専門としています。医師はマニパル大学でMBBSを取得し、マハデヴァ・ランプール医科大学グルバルガで医学のM.Dを取得し、チェンナイのCancer Institute (WIA)で腫瘍内科のDMを取得しました。

いくつかの医療評議会に認定されており、デリー医療評議会、カルナータカ医療評議会、血液学および幹細胞学会、The Connective Tissue Oncology Society、Musculoskeletal Tumor Society、American Head and Neck Societyのメンバーです。

アショク・ヴァイド博士は、グルガオンのメダンタ病院で医療および小児腫瘍学、血液学、骨髄移植部門の会長を務める著名な腫瘍学者です。彼に関する重要なポイントは以下の通りです：

• 臓器特異的ながん、白血病、リンパ腫の治療の専門知識
• 化学療法および骨髄移植、臓器特異的ながん治療、固形腫瘍、白血病、リンパ腫に特別な関心を持つ
• メダンタ - ザ・メディシティ、グルガオンの会長
• アーテミス病院、グルガオンの部門長
• 上級コンサルタント、プシュパンジャリ・クロスレイ病院
• 上級研修医、タタ・メモリアル病院、ムンバイ
• MBBS、1983年、ジャンム大学、J＆K
• MD、1989年、ジャンム大学、J＆K
• DM、1993年、Dr.MGR医科大学、チェンナイ

Dyt. Yaren Nur Güngör is a dietitian. She graduated from the Faculty of Nutrition and Dietetics. She provides evidence-based, personalized nutrition counseling in English. She designs tailored programs for health promotion, disease management, and weight control.

Her clinical focus includes diet plans for diabetes, heart disease, thyroid disorders, and other metabolic issues. She also guides weight loss and gain and improves body composition. She offers sports nutrition and nutrition care for children and teens. She provides preventive nutrition with lifestyle counseling. Her approach is patient-centered and motivating.